Cenderitide: Completed Phase II enrollment

Capricor completed enrollment of 14 patients in an open-label, dose-escalation,

Read the full 104 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE